Kai Chu

机构：Centers for Disease Control and Prevention, Xuzhou Medical College, International Marine and Dredging Consultants, Jiangsu Provincial Center for Disease Control and Prevention · ORCID：0009-0009-2653-3562

发表论文 88 篇 · 总被引 4146 次 · h-index 25

代表论文

• Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18–26 years in China: a randomised blinded clinical trial (2023 · The Lancet Infectious Diseases · 被引 45)
• Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial (2023 · 中国科学通报：英文版 · 被引 28)
• Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial (2023 · The Lancet Regional Health - Western Pacific · 被引 13)
• Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study (2023 · Vaccine · 被引 10)
• A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3–17 years (2025 · npj Vaccines · 被引 8)
• Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3–8 Years (2023 · Vaccines · 被引 6)